» Articles » PMID: 24876842

The Efficacy of Inositol and N-Acetyl Cysteine Administration (Ovaric HP) in Improving the Ovarian Function in Infertile Women with PCOS with or Without Insulin Resistance

Overview
Publisher Wiley
Date 2014 May 31
PMID 24876842
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective. Substances such as inositol and N-acetylcysteine (NAC) have been recently shown to be effective in treatment of PCOS patients. The aim of this prospective trial is to evaluate the efficacy of NAC + Inositol + folic acid on ovulation rate and menstrual regularity in PCOS patients with and without insulin resistance. Methods. Among the 91 PCOS patients treated with NAC + Inositol + folic, insulin resistance was present in 44 subjects (A) and absent in 47 (B). The primary endpoint was the ovulation rate/year, determined by menstrual diary, serum progesterone performed between 21° and 24° days, ultrasound findings of growth follicular or luteal cysts, and luteal ratio. HOMA-index assessment after 6 and 12 months of treatment was evaluated as secondary endpoint. Results. In both groups there was a significant increase in ovulation rate and no significant differences were found in the primary outcome between two groups. In group A, a significant reduction of HOMA-index was observed. Conclusions. The association NAC + Inositol + folic, regardless of insulin-resistance state, seems to improve ovarian function in PCOS patients. Therefore, inositol and NAC may have additional noninsulin-related mechanisms of action that allow achieving benefits also in those patients with negative HOMA-index.

Citing Articles

Clinical and Biochemical Potential of Antioxidants in Treating Polycystic Ovary Syndrome.

Cheng X, He B Int J Womens Health. 2022; 14:467-479.

PMID: 35392500 PMC: 8982783. DOI: 10.2147/IJWH.S345853.


Efficient production of myo-inositol in Escherichia coli through metabolic engineering.

You R, Wang L, Shi C, Chen H, Zhang S, Hu M Microb Cell Fact. 2020; 19(1):109.

PMID: 32448266 PMC: 7247202. DOI: 10.1186/s12934-020-01366-5.


N-Acetylcysteine Compared to Metformin, Improves The Expression Profile of Growth Differentiation Factor-9 and Receptor Tyrosine Kinase c-Kit in The Oocytes of Patients with Polycystic Ovarian Syndrome.

Cheraghi E, Mehranjani M, Shariatzadeh S, Nasr Esfahani M, Alani B Int J Fertil Steril. 2017; 11(4):270-278.

PMID: 29043702 PMC: 5641458. DOI: 10.22074/ijfs.2018.5142.


Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.

Sortino M, Salomone S, Carruba M, Drago F Front Pharmacol. 2017; 8:341.

PMID: 28642705 PMC: 5463048. DOI: 10.3389/fphar.2017.00341.


A Potential Therapeutic Role of Myoinositol in the Metabolic and Cardiovascular Profile of PCOS Iranian Women Aged between 30 and 40 Years.

Salehpour S, Nazari L, Hoseini S, Saharkhiz N, Ghazi F, Reza Sohrabi M Int J Endocrinol. 2016; 2016:7493147.

PMID: 27648072 PMC: 5014950. DOI: 10.1155/2016/7493147.


References
1.
De Mattia G, Bravi M, Laurenti O, Proietti A, De Luca O, Armiento A . Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia. 1998; 41(11):1392-6. DOI: 10.1007/s001250051082. View

2.
Unfer V, Carlomagno G, Dante G, Facchinetti F . Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012; 28(7):509-15. DOI: 10.3109/09513590.2011.650660. View

3.
Gerli S, Papaleo E, Ferrari A, Di Renzo G . Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007; 11(5):347-54. View

4.
Sirmans S, Pate K . Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014; 6:1-13. PMC: 3872139. DOI: 10.2147/CLEP.S37559. View

5.
Wu S, Divall S, Nwaopara A, Radovick S, Wondisford F, Ko C . Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 2014; 63(4):1270-82. PMC: 3964497. DOI: 10.2337/db13-1514. View